Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team Ligand (Nasdaq: LGND) on March 26, 2026 announced senior hires to expand its investments and business development team. The company named Peter Renehan, MD and Lee Brown as Vice Presidents of Investments and Business Development and promoted Lauren Hay to Vice President of Portfolio Strategy and Investments.All three will focus on sourcing and executing royalty financing opportunities and managing Ligand’s existing portfolio, reporting to Paul Hadden and supporting long‑term value creation for shareholders.

#LGND Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team

www.stocktitan.net/news/LGND/ligand-advance...

Ligand Reports Fourth Quarter and Full Year 2025 Financial Results Ligand (Nasdaq: LGND) reported strong fourth-quarter and full-year 2025 results with total revenues of $59.7M (Q4) and $268.1M (2025). Full-year royalty revenue grew 48%, to $161.0M. GAAP net income was $124.5M for 2025; core adjusted net income was $165.1M or $8.13 per diluted share. The company reaffirmed 2026 guidance: $245M–$285M revenue and adjusted EPS of $8.00–$9.00. Cash, cash equivalents and short-term investments totaled $733.5M as of December 31, 2025.Key commercial and clinical updates include regulatory filings, positive Phase 3/2 readouts across partnered programs, and recent transactions affecting contract revenue and royalties.

#LGND Ligand Reports Fourth Quarter and Full Year 2025 Financial Results

www.stocktitan.net/news/LGND/ligand-reports...

ICAO: 3FF94C
Flt: DMKMH D-MKMH LGND
Time: 2026-02-01 13:42:37 CET
Min Alt: 1850 ft
Min Dist: 8.2 nm (8° N)
Squawk: 7000

dev adsb planefence by kx1t -•sdr-e•airplanes•flightaware

ICAO: 3FF94C
Flt: DMKMH D-MKMH LGND
Time: 2025-12-21 10:25:42 CET
Min Alt: 1525 ft
Min Dist: 8.1 nm (11° N)
Squawk: 7000

dev adsb planefence by kx1t -•sdr-e•airplanes•flightaware

ICAO: 3FF94C
Flt: DMKMH D-MKMH LGND
Time: 2025-12-16 12:13:57 CET
Min Alt: 1400 ft
Min Dist: 7.92 nm (11° N)
Squawk: 7000

dev adsb planefence by kx1t -•sdr-e•airplanes•flightaware

#LGND: 2025 Analyst Day buff.ly/KgoVbOg

Citi spotlights Ligand as 'Goldilocks’ pick' for conservative biotech investors – Oninvest Equity investors should take a closer look at mid-cap Ligand Pharmaceuticals for a more conservative bet on the biotech industry, Citigroup argues. In his initiation report (as quoted by CNBC ), Citi ...

Citigroup has initiated coverage of #LGND with a Buy rating and a $270 target, calling it a “Goldilocks” biotech pick thanks to its diversified royalty portfolio. Citi says the approach reduces volatility while preserving upside. Details: en.oninvest.com/article/citi...

Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance Ligand (Nasdaq: LGND) hosted an Investor Day on Dec 9, 2025 and introduced 2026 guidance. The company forecasted 2026 total revenue $245m–$285m, including royalty revenue $200m–$225m (about a 40% increase vs 2025) and core adjusted EPS $8.00–$9.00. Ligand reiterated 2025 guidance of core revenue $225m–$235m and outlined a 5-year royalty receipts outlook of ≥23% CAGR. Management highlighted drivers including Filspari, Ohtuvayre, Capvaxive, Qarziba, and Zelsuvmi, noted $1 billion of deployable capital for royalty investments, and described Captisol and NITRICIL as royalty-generating platforms. The Investor Day was webcast live with presentation replay available on the company website.

#LGND Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance

www.stocktitan.net/news/LGND/ligand-hosts-2...

#LGND: Target Up On Improved Growth Outlook buff.ly/3KAJ8jQ

#LGND Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance

www.stocktitan.net/news/LGND/ligand-reports...

Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering Ligand Pharmaceuticals (Nasdaq: LGND) has announced the pricing of $400 million convertible senior notes due 2030 in a private placement to qualified institutional buyers. The notes will carry a 0.75% annual interest rate, payable semiannually, with an initial conversion price of $194.79 per share, representing a 32.5% premium over the current stock price.The company expects net proceeds of $386.9 million (or $445.1 million if the initial purchasers exercise their option). Ligand will use $39.9 million for convertible note hedge transactions, $15.0 million to repurchase 102,034 shares of common stock, and the remainder for general corporate purposes. The notes include provisions for conversion, redemption, and repurchase under specific conditions.

#LGND Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering

www.stocktitan.net/news/LGND/ligand-announc...

#LGND: Getting In Tune with MedTech buff.ly/ZZ1Vlco

Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030 Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today its intention to offer $400.0 million aggregate principal amount of convertible senior notes due 2030 (the “notes”) in a private placement (the “offering”) to persons

#LGND Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030

www.stocktitan.net/news/LGND/ligand-announc...

Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance Ligand Pharmaceuticals (Nasdaq: LGND) reported strong Q2 2025 financial results and raised its full-year guidance. Total revenue reached $47.6 million, up 15% year-over-year, driven by a 57% increase in royalty revenue to $36.4 million. The company raised its 2025 guidance, now expecting total revenue of $200-225 million and adjusted EPS of $6.70-7.00.Key highlights include the completion of the Pelthos Therapeutics merger, a $40 million strategic investment in Orchestra BioMed, and the commercial launch of Zelsuvmi. The company maintains a strong financial position with $245 million in cash and investments, including $26.5 million in Viking Therapeutics stock.

#LGND Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance

www.stocktitan.net/news/LGND/ligand-reports...

Exclusive: LGND wants to make ChatGPT for the Earth | TechCrunch LGND has raised $9 million to convert geographic data into vector embeddings to power AI models that understand the Earth.

I’ve known the founders of LGND.AI for years. They’re thoughtful, capable, and working on a huge problem: making Earth data useful, searchable as the Internet.

Thrilled to join their $9M round.

👉 Details: techcrunch.com/2025/07/10/l...

#LGND #GeoAI #ArtificialIntelligence #EarthObservation

LGND wants to make ChatGPT for the Earth LGND has raised $9 million to convert geographic data into vector embeddings to power AI models that understand the Earth.

#Climate #AI #Exclusive #embedding #geospatial #analytics #Javelin #Ventures #geospatial #data #LGND

Origin | Interest | Match

LGND wants to make ChatGPT for the Earth LGND has raised $9 million to convert geographic data into vector embeddings to power AI models that understand the Earth.

#AI #Climate #embedding #Exclusive #geospatial #analytics #geospatial #data #Javelin #Ventures #LGND

Origin | Interest | Match

LGND wants to make ChatGPT for the Earth LGND has raised $9 million to convert geographic data into vector embeddings to power AI models that understand the Earth.

#AI #Climate #Exclusive #embedding #geospatial #analytics #Javelin #Ventures #geospatial #data #LGND

Origin | Interest | Match

Breakthrough: First-Ever At-Home Treatment for Molluscum Launches - Ligand Secures $5M Milestone Payment First FDA-approved at-home treatment for molluscum launches commercially. Ligand earns $5M milestone, owns 56% stake, and gets 13% royalties. See launch details.

#LGND Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™

www.stocktitan.net/news/LGND/ligand-partner...

Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics Ligand Pharmaceuticals (Nasdaq: LGND) has completed its merger between subsidiary LNHC, Inc. and Channel Therapeutics' subsidiary CHRO Merger Sub Inc. The combined entity, Pelthos Therapeutics, will trade on NYSE American under ticker "PTHS" starting July 2, 2025.Concurrent with the merger, Pelthos raised $50.1 million in equity capital, with $32 million from the Murchinson-led investor group and $18 million from Ligand. The company is preparing to launch ZELSUVMI™, an FDA-designated novel drug for Molluscum contagiosum infections, in July 2025. Ligand will receive a 13% royalty on worldwide ZELSUVMI sales.ZELSUVMI is the first home-administered prescription treatment for molluscum, a condition affecting an estimated 16.7 million people in the US. Pelthos will also evaluate Channel's NaV 1.7 programs for various pain treatments.

#LGND Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics

www.stocktitan.net/news/LGND/ligand-announc...

Insider Buying Week 05-16-25 The Best Insider Buy/Sell Ratio in a Year The busiest week we’ve seen in some time.  In fact, it’s so busy that I would venture to say that […]

mother of all pharma and bio ramps. But maybe that never happens.
What's your take on the biotech sector's political headwinds despite strong company fundamentals?
www.theinsidersfund.com/2025/05/insi...
#InsiderBuying #Biotech #NotInvestmentAdvice #LGND #HealthcareInvesting #EconSky

Ligand to Ring the Nasdaq Opening Bell on May 19, 2025 Ligand Pharmaceuticals (LGND) has announced it will ring The Nasdaq Stock Market Opening Bell on Monday, May 19, 2025. CEO Todd Davis, along with senior management and board members, will participate in the ceremony to celebrate recent company milestones, including two value-creating transactions.Davis highlighted Ligand's transformation into a profitable, infrastructure-light organization that focuses on acquiring and generating royalties from a diverse biopharmaceutical product portfolio. The company aims to continue building on its two-year momentum, supporting partner development of breakthrough medicines, and creating long-term shareholder value. The ceremony will be broadcast live at 9:15 a.m. Eastern Time.

#LGND Ligand to Ring the Nasdaq Opening Bell on May 19, 2025

www.stocktitan.net/news/LGND/ligand-to-ring...

#LGND: 1Q:25 Results buff.ly/9AE4A7J

Ligand Reports First Quarter 2025 Financial Results Ligand Pharmaceuticals (LGND) reported strong Q1 2025 financial results with total revenues of $45.3 million, up 46% from Q1 2024. Portfolio royalty revenue grew 44% to $27.5 million, driven by Recordati's Qarziba and Travere's Filspari. However, the company posted a GAAP net loss of $42.5 million ($2.21 per share), compared to net income of $86.1 million in Q1 2024. Core adjusted net income was $26.6 million ($1.33 per diluted share). The company reaffirmed its 2025 guidance with expected total revenue of $180-200 million and adjusted EPS of $6.00-$6.25. Key strategic moves include a merger agreement with Channel Therapeutics for ZELSUVMI commercialization and a $50 million royalty investment in Castle Creek Biosciences' D-Fi Phase 3 study.

#LGND Ligand Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/LGND/ligand-reports...

AGORA LEGENDÁRIO 124128, A #AGILIDADE está ON na #ESCALADA e no #SUCESSO!

Saiba como foi:

YouTube:
youtu.be/pcYHAvC9-6k

Instagram:
www.instagram.com/p/DJW2oYkhImL

LinkedIn:
www.linkedin.com/posts/andrer...

#andrersanches #lgnd #homens #legendarios #legendariosbrasil #legendariossp #saopaulo

#LGND: Pelthos To Become Public Company buff.ly/FeAYZq5

Groundbreaking Skin Treatment Powers $50M Merger: First-Ever FDA-Approved Home Therapy for Molluscum Novel ZELSUVMI treatment drives Pelthos-Channel merger with $50M funding. First FDA-approved home therapy for widespread skin condition. See growth potential.

#LGND Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics

www.stocktitan.net/news/LGND/ligand-subsidi...

#LGND: First Steps into Cell & Gene Therapy buff.ly/6Kjzu0d

Can Ligand's Triple FDA Wins Offset Its $31M Q4 Loss? Revenue Jumps 52% Despite posting a Q4 net loss, Ligand saw 52% revenue growth and secured three FDA approvals for potential blockbuster products while maintaining strong 2025 guidance.

#LGND Ligand Reports Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/LGND/ligand-reports...

Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences Capital will fund Castle Creek’s D-Fi Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa through topline data results Ligand invested $50 million and a syndicate of co-investors...

Ligand Pharma invests $50mm in syndicate funding Castle Creek’s D-Fi Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa. D-Fi is an injectable autologous gene-modified cell therapy candidate.
#LGND
finance.yahoo.com/news/ligand-...